Inducing and maintaining remission in ulcerative colitis: Role of high-dose, extended-release mesalamine

Journal of Clinical Gastroenterology

Volumn 44, Issue 8, 2010, Pages 531-535

  Kao, James ^a   Kwok, Karl ^a   Das, Kiron M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

extended release mesalamine; inflammatory bowel disease; sulfasalazine; ulcerative colitis

Indexed keywords

APRISO; BALSALAZIDE; MESALAZINE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; ENCAPSULATION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; PANCREATITIS; PERICARDITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SYNCOPE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MESALAMINE; REMISSION INDUCTION; SULFASALAZINE;

EID: 77955982947     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181db1a61     Document Type: Review

References (21)

1. Jewell DP. 14.11: Ulcerative colitis. In: Warrell DA, Cox TM, Firth JD, eds. Oxford Textbook of Medicine. Oxford: Oxford University Press; 2005:612-620.
2. Jewell DP. Ulcerative Colitis - Before and After Hurst. [2006 Sir Arthur Hurst Lecture, British Society of Gastroenterology]. [cited December 22, 2009] Available from: http://www.bsg. org.uk/education/general/sir-arthur-hurst- lectures.html.
3. Svartz N. Salazopyrin: a new sulfonamide preparation. A. Therapeutic result in rheumatoid arthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations on treatment with sulfanilamide preparations. Acta Med Scand. 1942; 110:577-590.
4. Das KM, Dubin R. Clinical pharmacokinetics of sulfasalazine. Clin Pharmacokinet. 1976;1:406-425.
5. Das KM, Eastwood MA, McManus JPA, et al. The metabolism of salicylazosulfapyridine in ulcerative colitis. I. The relationship between metabolites and response to treatment of in-patients. Gut. 1973;14:631-637.
6. Das KM, Eastwood MA, McManus JPA, et al. Adverse reactions during salicylazosulfapyridine therapy and the relationship with medication metabolism and acetylator phenotype. NEJM. 1973;289:491-495.
7. Das KK, Bajpai M, Kong Y, et al. Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol. 2009;76:183-191.
8. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
9. Cohen HD, Das KMThe metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent." J Clin Gastroenterology. 2006;40(suppl. 3):s150-s154.
10. Asacols FDA Prescribing Information.
11. Asacols HD FDA Prescribing Information.
12. Pentasas FDA Prescribing Information.
13. Kamm MA, Sandborn WJ, Gassull M, et alOnce-daily, high-concentration MMX mesalamine in active ulcerative colitis." Gastroenterology. 2007;132:66-75.
14. Aprisot FDA Prescribing Information.
15. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800mg tablets) compared with 2.4 g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007;21:827-834.
16. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayedrelease oral mesalamine at 4.8 g/d (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
17. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137:1934-1943.
18. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of onceor twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
19. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57: 893-902.
20. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92: 1894-1898.
21. Kirsner JB. Department of Medical History: historical origins of medical and surgical therapy for inflammatory bowel disease. Lancet. 1998;352:1303-1305.